Hématologie
MENULower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments Volume 25, issue 2, Mars-Avril 2019
Export citation
Citation of this article, in the « Vancouver » format:
Christine Biron-Andréani, Isabelle Diaz, Robert Navarro, Jean-François Schved. Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments. Hématologie. 2019;25(2):93-99. doi:10.1684/hma.2019.1461